DUBLIN--(BUSINESS WIRE)--The "Global Female Contraceptives Market - Segmented by Type of Contraceptive Drug, Device, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global female contraceptives market is estimated to grow at a CAGR of 8.5% during the forecast period.
When contraception is affordable, abortion should rarely be necessary. The abortion rate is now at an all-time low in the developed countries - it dropped by more than 40 % over the past 25 years. This is because many anti-abortion groups have grown louder in many European countries, in the recent years.
In the United States, the teen pregnancy rate is substantially higher than in other western industrialized nations. According to a report published in 2016, there were 62 million American women in their childbearing years (15-44). About 43 million of them (70%) were at risk of unintended pregnancy, i.e., they were sexually active and do not want to get pregnant; however, they could become pregnant if they fail to use a contraceptive method correctly and consistently.
Center for Disease Control and Prevention (CDC) identified the need to curb this growth of unwanted pregnancies, and has taken up initiatives to educate and prevent unwanted abortions and pregnancies - emphasis on the usage of contraceptive pills, is one such initiative. So, the rate of abortion is drastically reducing and the usage of contraceptives such as oral contraceptives usage is increasing.
The other factors, like the government and NGO initiatives to promote contraception and the emphasis on family planning, are driving the market.
In North America, the United States is dominating the female contraceptives market, due to the maximum percentage of the female population in North America that uses the modern contraceptives techniques. Asia-Pacific is expected to record a substantial growth over the forecast period, due to the increasing awareness among people and several government initiatives.
Key Developments in the Market
- October 2017: Lupin acquired Symbiomix Therapeutics LLC.
- June 2017: Johnson & Johnson acquired Actelion.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- Bayer Healthcare AG
- Mayer Laboratories Inc.
- Pfizer Inc.
- Mylan Pharmaceuticals Inc.
- Teva Women's Health Inc.
- Merck & Co.
- Johnson & Johnson Ltd
- Lupin Pharmaceuticals Ltd
- The Female Health Company
- Fuji Latex Co. Ltd.
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/2rvmwb/global_female?w=4
